Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975287 | 0.92 | PIK3CD (0.72) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL976148 | 0.90 | PIK3CD (0.67) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL975962 | 0.88 | PIK3CD (0.69) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL2247563 | 0.88 | PIK3CD (0.47) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL957641 | 0.84 | PIK3CD (0.75) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Trifluoroacetic Acid SCHEMBL2246210 | 0.83 | PIK3CD (0.44) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL974613 | 0.83 | PIK3CD (0.71) | PIK3CD | |
| SCHEMBL957456 | 0.82 | PIK3CD (0.79) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL975925 | 0.79 | PIK3CD (0.79) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| Trifluoroacetic Acid SCHEMBL975061 | 0.79 | PIK3CD (0.64) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | claimed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | claimed |
| US-9975907-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-05-22 | — | — | US | claimed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | claimed |
| EP-2448938-B9 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2015-06-10 | — | — | EP | claimed |
| EP-2845856-A1 | Pyrimidinones as PI3K inhibitors | Incyte Corporation (US) | 2015-03-11 | — | — | EP | claimed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | claimed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | claimed |
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2448938-A1 | PYRIMIDINONES AS PI3K INHIBITORS | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2011008487-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008487-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885MERTK 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.